Application of Drug Testing Platforms in Circulating Tumor Cells and Validation of a Patient-Derived Xenograft Mouse Model in Patient with Primary Intracranial Ependymomas with Extraneural Metastases
暂无分享,去创建一个
Hsi-Che Liu | Ting-Chi Yeh | Jen-Yin Hou | Muh-Lii Liang | Shiu-Jau Chen | W. Ting | Tsung-Han Hsieh | Pao-Shu Wu | Che-Sheng Ho | Jia-Yun Huang | Man-Hsu Huang | Yi-Huei Ding | Chun-Chao Huang | Tsung-Yu Yen | Shih-Pei Wu | Jianzhou Zheng
[1] M. Furtak-Niczyporuk,et al. The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology , 2022, Expert review of pharmacoeconomics & outcomes research.
[2] C. Lockwood,et al. The "SEED" Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors. , 2022, Frontiers in bioscience.
[3] L. Strigari,et al. Extra-Neural Metastases From Primary Intracranial Ependymomas: A Systematic Review , 2022, Frontiers in Oncology.
[4] Ying Chen,et al. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma. , 2022, European journal of cancer.
[5] L. Ting,et al. Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer , 2021, Cancers.
[6] A. Drilon,et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors , 2021, Neuro-oncology.
[7] J. Won,et al. Molecular subtyping of ependymoma and prognostic impact of Ki-67 , 2021, Brain Tumor Pathology.
[8] J. Chiou,et al. Patient-Derived Tumor Chemosensitization of GKB202, an Antrodia Cinnamomea Mycelium-Derived Bioactive Compound , 2021, Molecules.
[9] M. Nowicki,et al. Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management , 2021, Biomedicines.
[10] R. Gibbs,et al. Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling. , 2021, JCO precision oncology.
[11] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[12] C. Fuller,et al. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study , 2021, Clinical Cancer Research.
[13] Qian Sun,et al. Identifying circulating glioma cells and their clusters as diagnostic markers by a novel detection platform , 2021, Clinical and translational medicine.
[14] Tsung-Han Hsieh,et al. Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas , 2020, Cancers.
[15] D. Ellison,et al. EPEN-54. ACNS0831, PHASE III RANDOMIZED TRIAL OF POST-RADIATION CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED EPENDYMOMA AGES 1 TO 21 YEARS , 2020, Neuro-Oncology.
[16] P. Chou,et al. Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer , 2020, Cancers.
[17] S. Chakrabarti,et al. Overexpression of Long Noncoding RNA HOTAIR Is a Unique Epigenetic Characteristic of Myxopapillary Ependymoma. , 2020, Journal of neuropathology and experimental neurology.
[18] M. Niewada,et al. Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years , 2020, Frontiers in Pharmacology.
[19] T. Jacques,et al. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups , 2020, Pediatric blood & cancer.
[20] A. Chatterjee,et al. Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma , 2020, Journal of Neuro-Oncology.
[21] Wei-Lin Jin,et al. Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model , 2019, Cancer Cell International.
[22] D. Franz,et al. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures , 2019, Expert review of neurotherapeutics.
[23] Yi-Wei Chen,et al. Irradiation-Induced Secondary Tumors following Pediatric Central Nervous System Tumors: Experiences of a Single Institute in Taiwan (1975-2013). , 2018, International journal of radiation oncology, biology, physics.
[24] K. Pajtler,et al. Ependymoma , 2018, Seminars in Neurology.
[25] T. Merchant,et al. Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. , 2018, International journal of radiation oncology, biology, physics.
[26] Yi-Wei Chen,et al. Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas , 2017, Oncotarget.
[27] Myrtle Davis,et al. Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies , 2017, Clinical Cancer Research.
[28] S. Partap,et al. Pediatric Ependymoma. , 2016, Journal of child neurology.
[29] F. Gilles,et al. A retrospective analysis of recurrent intracranial ependymoma , 2014, Pediatric blood & cancer.
[30] Sridhar Ramaswamy,et al. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.
[31] E. Thiele,et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.
[32] M. Berger,et al. Phase II study of pre‐irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: A report from the Children's Oncology Group , 2012, Pediatric blood & cancer.
[33] T. Merchant,et al. A 5-year investigation of children's adaptive functioning following conformal radiation therapy for localized ependymoma. , 2012, International journal of radiation oncology, biology, physics.
[34] Caroline Dive,et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] T. Molina,et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non‐small‐cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method , 2011, International journal of cancer.
[36] J. Villano,et al. Descriptive epidemiology of ependymal tumours in the United States , 2010, British Journal of Cancer.
[37] J. Lowe,et al. Pediatric Ependymoma: Biological Perspectives , 2009, Molecular Cancer Research.
[38] T. Merchant,et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.
[39] M. Rosenblum,et al. Ependymomas of the Central Nervous System and Adult Extra-axial Ependymomas are Morphologically and Immunohistochemically Distinct—A Comparative Study With Assessment of Ovarian Carcinomas for Expression of Glial Fibrillary Acidic Protein , 2008, The American journal of surgical pathology.
[40] L. Maaß. Occipital ependymoma with extracranial metastases. , 1954, Journal of neurosurgery.
[41] S. Hussein,et al. Diagnostic Pathology Cytokeratin Positivity in Myxopapillary Ependymoma – a Potential Diagnostic Pitfall , 2008 .